Vanguard Group
TXG icon

Vanguard Group’s 10x Genomics TXG Stock Holding History

Vanguard Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$212M Sell
13,017,914
-256,418
-2% -$3.87M ﹤0.01% 1521
2025
Q3 		$155M Buy
13,274,332
+834,272
+7% +$10.9M ﹤0.01% 1672
2025
Q2 		$144M Buy
12,440,060
+1,321,974
+12% +$12.1M ﹤0.01% 1665
2025
Q1 		$97.1M Buy
11,118,086
+184,537
+2% +$2.33M ﹤0.01% 1809
2024
Q4 		$157M Sell
10,933,549
-39,381
-0.4% -$621K ﹤0.01% 1652
2024
Q3 		$248M Buy
10,972,930
+783,673
+8% +$16.2M ﹤0.01% 1429
2024
Q2 		$198M Buy
10,189,257
+1,087,721
+12% +$28.5M ﹤0.01% 1503
2024
Q1 		$342M Buy
9,101,536
+90,204
+1% +$3.96M 0.01% 1213
2023
Q4 		$504M Buy
9,011,332
+107,815
+1% +$4.69M 0.01% 966
2023
Q3 		$367M Buy
8,903,517
+354,921
+4% +$18.5M 0.01% 1077
2023
Q2 		$477M Sell
8,548,596
-235,025
-3% -$12.7M 0.01% 951
2023
Q1 		$490M Buy
8,783,621
+363,610
+4% +$17M 0.01% 917
2022
Q4 		$307M Buy
8,420,011
+145,652
+2% +$4.76M 0.01% 1162
2022
Q3 		$236M Buy
8,274,359
+446,601
+6% +$17M 0.01% 1294
2022
Q2 		$354M Buy
7,827,758
+95,235
+1% +$4.94M 0.01% 1070
2022
Q1 		$588M Buy
7,732,523
+178,481
+2% +$15.6M 0.01% 866
2021
Q4 		$1.13B Sell
7,554,042
-50,002
-0.7% -$7.66M 0.03% 616
2021
Q3 		$1.11B Buy
7,604,044
+524,475
+7% +$90M 0.03% 598
2021
Q2 		$1.39B Buy
7,079,569
+551,232
+8% +$99.8M 0.03% 533
2021
Q1 		$1.18B Buy
6,528,337
+340,632
+6% +$58.8M 0.03% 563
2020
Q4 		$876M Buy
6,187,705
+233,287
+4% +$33.9M 0.03% 626
2020
Q3 		$742M Buy
5,954,418
+1,996,647
+50% +$210M 0.02% 616
2020
Q2 		$353M Buy
3,957,771
+2,873,055
+265% +$224M 0.01% 926
2020
Q1 		$67.6M Buy
1,084,716
+41,977
+4% +$3.28M ﹤0.01% 1718
2019
Q4 		$79.5M Buy
1,042,739
+315,312
+43% +$19M ﹤0.01% 1886
2019
Q3 		$36.7M Buy
+727,427
New +$40.3M ﹤0.01% 2216

Other funds holding TXG

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vanguard Group's TXG Position: Q4 2025 in Review

Vanguard Group reduced its 10x Genomics (TXG) stake by 1.9% in Q4 2025, selling an estimated $3.87M and leaving 13,017,914 shares worth $212M. The position accounts for ﹤0.01% of the portfolio, ranked #1521.

Vanguard Group first reported a position in TXG in Q3 2019 and has held it in 26 quarters since. The position peaked at $1.39B in Q2 2021. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Vanguard Group held 13,017,914 shares of 10x Genomics worth $212M as of Q4 2025.
  • Vanguard Group sold 256,418 10x Genomics shares in Q4 2025, an estimated $3.87M.
  • 10x Genomics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1521 holding.
  • Vanguard Group first reported a position in 10x Genomics in Q3 2019 and has held it in 26 quarters since.
  • Vanguard Group's 10x Genomics position peaked at $1.39B in Q2 2021.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.